advertisement
Abstract #25802 Published in IGR 12-2
A meta-analysis of therapy comparison between bimatoprost and timolol in ocular hypertention eye
Ge Y; Wang L; Cheng J; Huang ZChinese Ophthalmic Research 2009; 27: 1120-1125
Objective: Many researches have demonstrated the lowing-intraocular pressure (IOP) effects of bimatoprost and timolol. However, no powerful evidence showed which drug has the better efficacy. This study was to perform a meta-analysis to evaluate the efficacy and tolerability of bimatoprost compared with latanoprost in lowing IOP. Methods: This was a evidence-based medicine science study. Pertinent studies were identified through searches of PubMed, EMBASE, the Cochrane Liberary Controlled Trials Register and Chinese Biomedicine Database using the terms of timolol, blocardren, temserin, timoptic, bimatoprost, lumigan. The intensive searching by hand and up to October 1, 2008 was also designed. Results: Six randomized and controlled studies enrolling a total of 2094 patients were included in the meta-analysis and three clinical indexes were analyzed. Bimatoprost was associated with greater decline value from baseline IOP in comparison with timolol (P < 0.01) with a weight mean difference -2.04 at final point (95% CI: -2.44 to -1.64). Numerically greater proportions of bimatoprost patients than timolol patients achieved the target IOP at 3 months (from 3 literature) and > 6 months (from 2 literature) with a pooled RR of 1.87 (95% CI: 1.45 to 2.41), 1.60 (95% CI: 1.36 to 1.90) (P < 0.01), respectively. Bimatoprost showed a more frequencies in the adverse effects such as conjunctival hyperemia and eyelash growth than timolol with an RR of 4.18 (95% CI: 2.89 to 6.05), 9.40 (95% CI: 5.62 to 15.71). No obvious drug-related side effect was found from literature analysis included both drugs. Conclusion: Searched literature offers grade A of evidences for the comparison clinical evaluation of therapy efficacy between bimatoprost and timolol in lowing IOP. Bimatoprost has a better efficacy in lowering IOP and reaching comparable proportions of patients with target IOP than timolol. Both agents are well tolerated. LA: Chinese
Y. Ge. Department of Ophthalmology, Nanjing General Hospital of Nanjing Military Command, Nanjing 210002, China. zjgyr@hotmail.com
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
